Chemotherapy for malignant pleural mesothelioma: Past results and recent developments

Lung Cancer

Volumn 45, Issue SUPPL., 2004, Pages

  Tomek, Sandra ^a   Manegold, Christian ^b  

^a Division of Oncology   (Austria)

^b Thoraxklinik Heidelberg   (Germany)

Author keywords

Chemotherapy; Malignant pleural mesothelioma

Indexed keywords

5,6 DIHYDROAZACITIDINE; AMSACRINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIAZIQUONE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PIRARUBICIN; PLATINUM DERIVATIVE; RALTITREXED; RANPIRNASE; RECOMBINANT ALPHA INTERFERON; TAMOXIFEN; UNINDEXED DRUG; ZORUBICIN;

CANCER CHEMOTHERAPY; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZATION; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; QUALITY OF LIFE;

EID: 3142768949     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.020     Document Type: Conference Paper

References (153)

1. Peto J., Hodgson J.T., Matthews F.E., Jones J.R. Continuing increase in mesothelioma mortality in Britain. Lancet. 345:1995;535-539
2. Connelly R.R., Spirtas R., Myers M.H., Percy C.L., Fraumeni J.F. Jr. Demographic patterns for mesothelioma in the United States. J. Natl. Cancer Inst. 78:1987;1053-1060
3. Selikoff I.J., Hammond E.C., Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 46:1980;2736-2740
4. Roggli V.L., Oury T.D., Moffatt E.J. Malignant mesothelioma in women. Anat. Pathol. 2:1997;147-163
5. Wagner J.C., Berry G., Pooley F.D. Mesotheliomas and asbestos type in asbestos textile workers: a study of lung contents. Br. Med. J. (Clin. Res. Ed.). 285:1982;603-606
6. Stanton M.F., Laynard M., Tegeris A., Miller E., May M., Kent E. Carcinogenicity of fibrous glass: pleural response in the rat in relation to fiber dimension. J. Natl. Cancer Inst. 58:1977;587-603
7. Rom W.N., Travis W.D., Brody A.R. Cellular and molecular basis of the asbestos-related diseases. Am. Rev. Respir. Dis. 143:1991;408-422
8. Mossman B.T., Kamp D.W., Weitzman S.A. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 14:1996;466-480
9. Pache J.C., Janssen Y.M., Walsh E.S., et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am. J. Pathol. 152:1998;333-340
10. Craighead J.E., Mossman B.T. The pathogenesis of asbestos-associated diseases. N. Engl. J. Med. 306:1982;1446-1455
11. Butel J.S., Lednicky J.A. Cell and molecular biology of simian virus 40: implications for human infections and disease. J. Natl. Cancer Inst. 91:1999;119-134
12. Carbone M., Fisher S., Powers A., Pass H.I., Rizzo P. New molecular and epidemiological issues in mesothelioma: role of SV40. J. Cell Physiol. 180:1999;167-172
13. Carbone M., Rizzo P., Pass H.I. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene. 15:1997;1877-1888
14. Rizzo P., Bocchetta M., Powers A., et al. SV40 and the pathogenesis of mesothelioma. Semin. Cancer Biol. 11:2001;63-71
15. Antman K.H., Corson J.M., Li F.P., et al. Malignant mesothelioma following radiation exposure. J. Clin. Oncol. 1:1983;695-700
16. Hofmann J., Mintzer D., Warhol M.J. Malignant mesothelioma following radiation therapy. Am. J. Med. 97:1994;379-382
17. Baris Y.I. Fibrous zeolite (erionite)-related diseases in Turkey. Am. J. Ind. Med. 19:1991;374-378
18. Stanton M.F., Wrench C. Mechanisms of mesothelioma induction with asbestos and fibrous glass. J. Natl. Cancer Inst. 48:1972;797-821
19. Weissmann B., Corson J.M., Neugut A.I., Antman K.H. Malignant mesothelioma following treatment for Hodgkin's disease. J. Clin. Oncol. 14:1996;2098-2100
20. Boutin C., Schlesser M., Frenay C., Astoul P. Malignant pleural mesothelioma. Eur. Respir. J. 12:1998;972-981
21. Rusch V.W., Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 111:1996;815-825. (discussion 825-826)
22. Bissett D., Macbeth F.R., Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin. Oncol. (R. Coll. Radiol.). 3:1991;315-317
23. Kutcher G.J., Kestler C., Greenblatt D., Brenner H., Hilaris B.S., Nori D. Technique for external beam treatment for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 1:1987;1747-1752
24. Soubra M., Dunscombe P.B., Hodson D.I., Wong G. Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 18:1990;1521-1527
25. Antman K.H., Blum R.H., Greenberger J.S., Flowerdew G., Skarin A.T., Canellos G.P. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am. J. Med. 68:1980;356-362
26. Hilaris B.S., Nori D., Kwong E., Kutcher G.J., Martini N. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 10:1984;325-331
27. Linden C.J., Mercke C., Albrechtsson U., Johansson L., Ewers S.B. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur. Respir. J. 9:1996;2565-2572
28. Ryan C.W., Herndon J., Vogelzang N.J. A review of chemotherapy trials for malignant mesothelioma. Chest. 113:1998;66S-73S
29. Taub R.N., Antman K.H. Chemotherapy for malignant mesothelioma. Semin. Thorac. Cardiovasc. Surg. 9:1997;361-366
30. Pass H.I., Temeck B.K., Kranda K., Steinberg S.M., Feuerstein I.R. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 115:1998;310-317. (discussion 317-318)
31. Steele J.P., Rudd R.M. Malignant mesothelioma: predictors of prognosis and clinical trials. Thorax. 55:2000;725-726
32. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J. Clin. Oncol. 16:1998;145-152
33. Aisner J., Wiernik P.H. Chemotherapy in the treatment of malignant mesothelioma. Semin. Oncol. 8:1981;335-343
34. Antman K.H., Corson J.M. Benign and malignant pleural mesothelioma. Clin. Chest. Med. 6:1985;127-140
35. Colbert N., Vannetzel J.M., Izrael V., et al. A prospective study of detorubicin in malignant mesothelioma. Cancer. 56:1985;2170-2174
36. Eisenhauer E.A., Evans W.K., Raghavan D., et al. Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat. Rep. 70:1986;1029-1030
37. Kaukel E., Koschel G., Gatzemeyer U., Salewski E. A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer. 66:1990;651-654
38. Magri M.D., Foladore S., Veronesi A., et al. Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann. Oncol. 3:1992;237-238
39. Magri M.D., Veronesi A., Foladore S., et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE) - Mesothelioma Committee. Tumori. 77:1991;49-51
40. Mattson K., Giaccone G., Kirkpatrick A., et al. Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Co-operative Group. J. Clin. Oncol. 10:1992;824-828
41. Sridhar K.S., Hussein A.M., Feun L.G., Zubrod C.G. Activity of pirarubicin (4′-o-tetrahydropyranyladriamycin) in malignant mesothelioma. Cancer. 63:1989;1084-1091
42. van Breukelen F.J., Mattson K, Giaccone G. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Co-operative Group. Eur. J. Cancer. 27:1991;1627-1629
43. Zidar B.L., Green S., Pierce H.I., Roach R.W., Balcerzak S.P., Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest. New Drugs. 6:1988;223-226
44. Mintzer D.M., Kelsen D., Frimmer D., Heelan R., Gralla R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat. Rep. 69:1985;711-712
45. Planting A.S., van der Burg M.E., Goey S.H., et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann. Oncol. 6:1995;613-615
46. Mbidde E.K., Harland S.J., Calvert A.H., Smith I.E. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother. Pharmacol. 18:1986;284-285
47. Raghavan D., Gianoutsos P., Bishop J., et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J. Clin. Oncol. 8:1990;151-154
48. Vogelzang N.J., Goutsou M., Corson J.M., et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother. Pharmacol. 27:1990;239-242
49. Bajorin D., Kelsen D., Mintzer D.M. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat. Rep. 71:1987;857-858
50. Sorensen P.G., Bach F., Bork E., Hansen H.H. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat. Rep. 69:1985;1431-1432
51. Alberts A.S., Falkson G., Van Zyl L. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J. Natl. Cancer Inst. 80:1988;698-700
52. Andersen M.K., Krarup-Hansen A., Martensson G., et al. Ifosfamide in malignant mesothelioma: a phase II study. Lung Cancer. 24:1999;39-43
53. Falkson G., Hunt M., Borden E.C., Hayes J.A., Falkson C.I., Smith T.J. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest. New Drugs. 10:1992;337-343
54. Icli F., Karaoguz H., Hasturk S., et al. Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer. 15:1996;207-213
55. Krarup-Hansen A. Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma. Lung Cancer. 16:1996;101-102
56. Zidar B.L., Metch B., Balcerzak S.P., et al. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer. 70:1992;2547-2551
57. Boutin C., Irisson M., Guerin J.C., et al. Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat. Rep. 71:1987;205-206
58. Cowan J.D., Green S., Lucas J., et al. Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest. New Drugs. 6:1988;247-248
59. Kelsen D., Gralla R., Cheng E., Martini N. Vindesine in the treatment of malignant mesothelioma: a phase II study. Cancer Treat. Rep. 67:1983;821-822
60. Martensson G., Sorenson S. A phase II study of vincristine in malignant mesothelioma - a negative report. Cancer Chemother. Pharmacol. 24:1989;133-134
61. Sahmoud T., Postmus P.E., van Pottelsberghe C., et al. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur. J. Cancer. 33:1997;2211-2215
62. Tammilehto L., Maasilta P., Mantyla M., Salo J., Mattson K. Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann. Oncol. 5:1994;949-950
63. Solheim O.P., Saeter G., Finnanger A.M., Stenwig A.E. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br. J. Cancer. 65:1992;956-960
64. Kindler H.L., Belani C.P., Herndon J.E. II, Vogelzang N.J., Suzuki Y., Green M.R. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 86:1999;1985-1991
65. Harvey V.J., Slevin M.L., Ponder B.A., Blackshaw A.J., Wrigley P.F. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer. 54:1985;961-964
66. Samuels B.L., Herndon J.E. II, Harmon D.C., et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer. 82:1998;1578-1584
67. Vogelzang N.J., Weissman L.B., Herndon J.E. II, et al. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study. J. Clin. Oncol. 12:1994;1436-1442
68. Vogelzang N.J., Herndon J.E. II, Cirrincione C., et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 79:1997;2237-2242
69. Ardizzoni A., Rosso R., Salvati F., et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer. 67:1991;2984-2987
70. Henss H., Fiebig H.H., Schildge J., Arnold H., Hasse J. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie. 11:1988;118-120
71. Chahinian A.P., Antman K., Goutsou M., et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J. Clin. Oncol. 11:1993;1559-1565
72. Pennucci M.C., Ardizzoni A., Pronzato P., et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer. 79:1997;1897-1902
73. Shin D.M., Fossella F.V., Umsawasdi T., et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer. 76:1995;2230-2236
74. Samson M.K., Wasser L.P., Borden E.C., et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J. Clin. Oncol. 5:1987;86-91
75. Carmichael J., Cantwell B.M., Harris A.L. A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur. J. Cancer Clin. Oncol. 25:1989;911-912
76. Dirix L.Y., van Meerbeeck J., Schrijvers D., et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann. Oncol. 5:1994;653-655
77. Zidar B.L., Benjamin R.S., Frank J., Lane M., Baker L.H. Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study. Am J. Clin. Oncol. 6:1983;71-74
78. Eisenhauer E.A., Evans W.K., Murray N., Kocha W., Wierzbicki R., Wilson K. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest. New Drugs. 6:1988;327-329
79. White S.C., Anderson H., Jayson G.C., Ashcroft L., Ranson M., Thatcher N. Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Ann. Oncol. 11:2000;201-206
80. Tsavaris N., Mylonakis N., Karvounis N., et al. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer. 11:1994;299-303
81. Middleton G.W., Smith I.E., O'Brien M.E., et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann. Oncol. 9:1998;269-273
82. Dimitrov N.V., Egner J., Balcueva E., Suhrland L.G. High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer. 50:1982;1245-1247
83. Gridelli C., Pepe R., Airoma G., et al. Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Tumori. 78:1992;380-382
84. Sterman D.H., Kaiser L.R., Albelda S.M. Advances in the treatment of malignant pleural mesothelioma. Chest. 116:1999;504-520
85. Boutin C., Nussbaum E., Monnet I., et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 74:1994;2460-2467
86. Christmas T.I., Manning L.S., Garlepp M.J., Musk A.W., Robinson B.W. Effect of interferon-alpha 2a on malignant mesothelioma. J. Interferon Res. 13:1993;9-12
87. Sklarin N.T., Chahinian A.P., Feuer E.J., Lahman L.A., Szrajer L., Holland J.F. Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res. 48:1988;64-67
88. Soulie P., Ruffie P., Trandafir L., et al. Combined systemic chemo-immunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J. Clin. Oncol. 14:1996;878-885
89. Tansan S., Emri S., Selcuk T., et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology. 51:1994;348-351
90. Metintas M., Ozdemir N., Ucgun I., et al. Cisplatin, mitomycin, and interferon-alpha2a combination chemo-immunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest. 116:1999;391-398
91. Pass H.W., Temeck B.K., Kranda K., Steinberg S.M., Pass H.I. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann. Surg. Oncol. 2:1995;214-220
92. O'Reilly E.M., Ilson D.H., Saltz L.B., Heelan R., Martin L., Kelsen D.P. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest. 17:1999;195-200
93. Upham J.W., Musk A.W., van Hazel G., Byrne M., Robinson B.W. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust. N.Z. J. Med. 23:1993;683-687
94. Parra H.S., Tixi L., Latteri F., et al. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer. 92:2001;650-656
95. Von Hoff D.D., Huong A.M. Effect of recombinant interferon-beta ser on primary human tumor colony-forming units. J. Interferon. Res. 8:1988;813-820
96. Von Hoff D.D., Metch B., Lucas J.G., Balcerzak S.P., Grunberg S.M., Rivkin S.E. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J. Interferon Res. 10:1990;531-534
97. Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995;72:1238-8.
98. Astoul P., Picat-Joossen D., Viallat J.R., Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 83:1998;2099-2104
99. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 2001;31303-10.
100. Taub RN, Keohan ML, Vogelzang NJ, et al. Phase II trial of Onconase® (ONC) in patients (PTS) with advanced malignant mesothelioma (MM): analysis of survival. Proc Annu Meet Am Soc Clin Oncol 1999;A2021.
101. Vogelzang N.J., Herndon J.E. II, Miller A., et al. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann. Oncol. 10:1999;597-600
102. Fong T.A., Shawver L.K., Sun L., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106
103. Mendel D.B., Laird A.D., Smolich B.D., et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 15:2000;29-41
104. Ohta Y., Shridhar V., Bright R.K., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer. 81:1999;54-61
105. Kindler HL, Vogelzang NJ, Chien K, et al. SU5416 in malignant mesothelioma: a University of Chicago Phase II Consortium Study. Proc Annu Meet Am Soc Clin Oncol 2001:A1359.
106. Fizazi K., Caliandro R., Soulie P., et al. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur. J. Cancer. 36:2000;1514-1521
107. Vogelzang N.J., Rusthoven J., Symanowski J., et al. A phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21:2003;2636-2644
108. Liepa A, Rusthoven J, Denham C, et al. Clinical benefit algorithm for malignant pleural mesothelioma: results from randomized trial of pemetrexed plus cisplatin versus cisplatin. Ann Oncol 2002;13:129(Suppl 5) [abstract 475 PD].
109. Hughes A., Calvert P., Azzabi A., et al. Phase I clinical and pharmacokinetics study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 20:2003;3533-3544
110. Ollikainen T., Knuuttila A., Suhonen S., et al. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents. Anticancer Drugs. 11:2000;93-99
111. van Meerbeeck J.P., Baas P., Debruyne C., et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Co-operative Group. Cancer. 85:1999;2577-2582
112. Kindler H.L., Millard F., Herndon J.E. II, Vogelzang N.J., Suzuki Y., Green M.R. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 31:2001;311-317
113. ®) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 17:1998;A1784
114. Byrne M.J., Davidson J.A., Musk A.W., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J. Clin. Oncol. 17:1999;25-30
115. Van Haarst JW, Burgers JA, Manegold CH, et al. Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM). In: Program and abstracts of the 9th World Conference on Lung Cancer; September 11-15, 2000, Tokyo, Japan [abstract 56].
116. Aversa S.L., Crcuri C., De Pangher V., et al. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma (MPM): a phase II study of the GSTPV. Ann. Oncol. 9:1998;117
117. Kindler HL, Herndon JE, Vogelzang NJ, Green MR. CPT-11 in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 9733). Proc Annu Meet Am Soc Clin Oncol 2000;A1978.
118. Nakano T., Chahinian A.P., Shinjo M., et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer. 85:1999;2375-2384
119. Verschraegen C, Le D, Kudelka A, Kavanagh J, Hunt K. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Proc Annu Meet Am Soc Clin Oncol 2001;A2210.
120. Maksymiuk A.W., Marschke R.F. Jr., Tazelaar H.D., et al. Phase II trial of topotecan for the treatment of mesothelioma. Am. J. Clin. Oncol. 21:1998;610-613
121. Baas P., van Meerbeeck J., Groen H., et al. Caelyx in malignant mesothelioma: a phase II EORTC study. Ann. Oncol. 11:2000;697-700
122. Oh Y., Perez-Soler R., Fossella F.V., et al. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest. New Drugs. 18:2000;243-245
123. Steele J.P., O'Doherty C.A., Shamash J., et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann. Oncol. 12:2001;497-499
124. Giaccone G, O'Brien M, Byrne MJ, Van Steenkiste J, Cosaert J. Phase II Trial of ZD0473 in patients with mesothelioma relapsing after one prior chemotherapy regimen. Proc Annu Meet Am Soc Clin Oncol 2001;A2781.
125. Shin DM, Walsh GL, Smythe WR, et al. Pathologic response with liposomal entrapped cisplatin (L-NDDP) administered in patients (pts) with malignant pleural mesothelioma (MPM): phase II clinical study. In: Program and abstracts of the 9th World Conference on Lung Cancer; September 11-15, 2000, Tokyo, Japan [abstract 57].
126. Steele J.P., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., Rudd R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J. Clin. Oncol. 18:2000;3912-3917
127. Steele JP, Shamsh J, Evans MT, Gower NH, Rudd RM. Phase II trial of vinorelbine and oxaliplatin in patients with malignant pleural mesothelioma. St. Bartholomew's Hospital, London, UK. In: Program and abstracts of the 9th World Conference on Lung Cancer; September 11-15, 2000, Tokyo, Japan [abstract 54].
128. van Meerbeeck J., Debruyne C., van Zandwijk N., et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br. J. Cancer. 74:1996;961-963
129. Juturi JV, Adelstein DJ, Rice TW, DeCamp MM, Murthy S, Larto MA. Intracavitary paclitaxel in the multimodality management of malignant pleural mesothelioma. Proc Annu Meet Am Soc Clin Oncol 2001;A1460.
130. Chahinian A.P., Mandeli J.P., Gluck H., Naim H., Teirstein A.S., Holland J.F. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J. Surg. Oncol. 67:1998;104-111
131. Bednar ME, Chahinian P. Paclitaxel and carboplatin for malignant mesothelioma. Annu Meet Am Soc Clin Oncol 1999;A1916.
132. Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH. Docetaxel for malignant mesothelioma: phase ii study of the Eastern Cooperative Oncology Group (ECOG 2595). Proc Am Soc Clin Oncol 1999;A1829.
133. Vorobiof DA, Chasen MR, Abratt R, et al. Taxotere in malignant pleural mesothelioma: a phase II clinical trial. In: Program and abstracts of the 9th World Conference on Lung Cancer; September 11-15, 2000, Tokyo, Japan [abstract 58].
134. Knuuttila A., Ollikainen T., Halme M., et al. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility study. Anticancer Drugs. 11:2000;257-261
135. Lerner H.J., Schoenfeld D.A., Martin A., Falkson G., Borden E. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer. 52:1983;1981-1985
136. Vogelzang N, Taub R, Shin D, et al. Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis of Survival. Proc Annu Meet Am Soc Clin Oncol 2000;A2274.
137. Scagliotti G., Shin D., Kindler H., Johnson D., Keppler U. Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma. Eur. J. Cancer. 37(Suppl. 6):2001;20
138. Ardizzoni A., Pennucci M.C., Castagneto B., et al. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am. J. Clin. Oncol. 17:1994;80-82
139. Davidson J.A., Musk A.W., Wood B.R., et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J. Immunother. 21:1998;389-398
140. Webster I., Cochrane J.W., Burkhardt K.R. Immunotherapy with BCG vaccine in 30 cases of mesothelioma. S. Afr. Med. J. 61:1982;277-278
141. Falkson G., Vorobiof D.A., Lerner H.J. A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemother. Pharmacol. 11:1983;94-97
142. Eagan R.T., Frytak S., Richardson R.L., Creagan E.T., Nichols W.C. Phase II trial of diaziquone in malignant mesothelioma. Cancer Treat. Rep. 70:1986;429
143. Falkson G., Vorobiof D.A., Simson I.W., Borden E.C. Phase II trial of acivicin in malignant mesothelioma. Cancer Treat. Rep. 71:1987;545-546
144. Cantwell B.M., Earnshaw M., Harris A.L. Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat. Rep. 70:1986;1335-1336
145. Chahinian A.P., Holland J.F., Mandel E.M. Chemotherapy for malignant mesothelioma with adriamycin and continuous infusion of 5-azacytidine. Cancer Treat. Rep. 62:1978;1108-1109
146. Breau JL, Boaziz C, Morere JJF. Combination chemotherapy with cisplatinum, adriamycin, bleomycin and mitomycin, plus systemic and intra-pleural hyaluronidase in 25 consecutive cases of stages II, III pleural mesotheliom. In: First International Mesothelioma Conference 1991, p. 5.
147. Trandafir L., Ruffie P., Borel C., et al. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur. J. Cancer. 33:1997;1900-1902
148. Thodtmann R., Depenbrock H., Blatter J., Johnson R.D., van Oosterom A., Hanauske A.R. Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors. Semin. Oncol. 26:1999;89-93
149. Bretti S., Berruti A., Dogliotti L., et al. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori. 84:1998;558-561
150. Halme M., Knuuttila A., Vehmas T., et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br. J. Cancer. 80:1999;1781-1785
151. Pinto C., Marino A., Guaraldi M., et al. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am. J. Clin. Oncol. 24:2001;143-147
152. Calvert H, Hughes AN, Calvert PM, Plummer RE, Highley MS. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma ina a phase I trial. Proc Annu Meet Am Soc Clin Oncol 2000;A1936.
153. Herdon J.E., Green M., Chahinian A.P., Corson J.M., Suzuki Y., Vogelzang N.J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 113:1998;723-731